Torisel among new approval recommendations in Japan

Wyeth/Pfizer's infused mTOR kinase inhibitor, Torisel (temsirolimus), has been recommended for approval in Japan for the treatment of advanced renal cell carcinoma (RCC).

Wyeth/Pfizer's infused mTOR kinase inhibitor, Torisel (temsirolimus), has been recommended for approval in Japan for the treatment of advanced renal cell carcinoma (RCC).

The product stands to become the second in its class to be launched for this indication in the country, following...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.